Клиническое значение антител к DFS70 при иммуновоспалительных ревматических заболеваниях (обзор)

Актуальность проблемы иммуновоспалительных ревматических заболеваний (ИВРЗ) для современной медицины определяется их высокой распространенностью в популяции, трудностью ранней диагностики, быстрым развитием инвалидности и неблагоприятным жизненным прогнозом. Последние данные о значимости антител к DFS70 (анти-DFS70) открыли новые возможности для оптимизации поэтапной диагностики ИВРЗ. Выявление данных антител может помочь в интерпретации положительного результата определения антинуклеарных антител (АНА) методом непрямой реакции иммунофлюоресценции на клетках HEp-2 линии при отсутствии аутоантител, специфичных для ИВРЗ. Выявление анти-DFS70 у серопозитивных по АНА пациентов без клинических и/или серологических маркеров, характерных для определенного заболевания из группы ИВРЗ, может рассматриваться в качестве потенциального маркера, исключающего данную группу заболеваний.

1. Goldblatt F, O’Neill SG. Clinical aspects of autoimmune rheumatic diseases. Lancet. 2013;382(9894):797-808. doi: 10.1016/S0140-6736(13)61499-3

2. Davidson A, Diamond B. Autoimmune diseases. N Engl J Med. 2001;345(5):340-350. doi: 10.1056/NEJM200108023450506

3. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725. doi: 10.1002/art.1780400928

4. Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677-2686. doi: 10.1002/art.34473

5. Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Ann Rheum Dis. 2019;78(9): 1151-1159. doi: 10.1136/annrheumdis-2018-214819

6. van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, et al. 2013 classification criteria for systemic sclerosis: An American college of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2013;72(11):1747-1755. doi: 10.1136/annrheumdis-2013-204424

7. Shiboski SC, Shiboski CH, Criswell L, Baer A, Challacombe S, Lanfranchi H, et al.; Sjögren’s International Collaborative Clinical Alliance (SICCA) Research Groups. American College of Rheumatology classification criteria for Sjögren’s syndrome: A datadriven, expert consensus approach in the Sjögren’s International Collaborative Clinical Alliance cohort. Arthritis Care Res (Hoboken). 2012;64(4):475-487. doi: 10.1002/acr.21591

8. Arbuckle MR, McClain MT, Rubertone MV, Scofield RH, Dennis GJ, James JA, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003;349(16):1526-1533. doi: 10.1056/NEJMoa021933

9. Eriksson C, Kokkonen H, Johansson M, Hallmans G, Wadell G, Rantapää-Dahlqvist S. Autoantibodies predate the onset of systemic lupus erythematosus in northern Sweden. Arthritis Res Ther. 2011;13(1):R30. doi: 10.1186/ar3258

10. Насонов ЕЛ, Соловьев СК, Арш инов АВ. Системная красная волчанка: история и современность. Научно-практическая ревматология. 2022;60(4):397-412. doi: 10.47360/1995-4484-2022-397-412

11. Насонов ЕЛ, Попкова ТВ, Панафидина ТА. Проблемы ранней диагностики системной красной волчанки в период пандемии COVID-19. Научно-практическая ревматология. 2021;59(2):119-128. doi: 10.47360/1995-4484-2021-119-128

12. Lambers WM, Westra J, Jonkman MF, Bootsma H, de Leeuw K. Incomplete systemic lupus erythematosus – what remains after application of ACR and SLICC criteria? Arthritis Care Res. 2020;72(5):607-614. doi: 10.1002/acr.23894

13. Насонов ЕЛ (ред.). Ревматология. Российские клинические рекомендации. М.:ГЭОТАР-Медиа;2017.

14. Agmon-Levin N, Damoiseaux J, Kallenberg C, Sack U, Witte T, Herold M, et al. International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies. Ann Rheum Dis. 2014;73(1):17-23. doi: 10.1136/annrheumdis-2013-203863

15. Solomon DH, Kavanaugh AJ, Schur PH. American College of Rheumatology Ad Hoc Committee on Immunologic Testing guidelines. Evidence-based guidelines for the use of immunologic tests: Antinuclear antibody testing. Arthritis Rheum. 2002;47(4):434-444. doi: 10.1002/art.10561

16. Александрова ЕН, Верижникова ЗГ, Новиков АА, Лукина ГВ. Современный взгляд на проблемы исследования антинуклеарных антител при системной красной волчанке (обзор литературы). Клиническая лабораторная диагностика. 2018;63(6):340-348. doi: 10.18821/0869-2084-2018-63-6-340-348

17. Kang SY, Lee WI, Kim MH, La Jeon Y. Clinical use of antiDFS70 autoantibodies. Rheumatol Int. 2019;39(8):1423-1429. doi: 10.1007/s00296-019-04299-4

18. Насонов ЕЛ, Александрова ЕН, Новиков АА. Аутоиммунные ревматические болезни – проблемы иммунопатологии и персонифицированного лечения. Анналы Российской академии медицинских наук. 2015;70(2):169-182. doi: 10.15690/vramn.v70i2.1310

19. Carter JB, Carter S, Saschenbrecker S, Goeckeritz BE. Recognition and relevance of Anti-DFS70 autoantibodies in routine antinuclear autoantibodies testing at a community hospital. Front Med (Lausanne). 2018;5:88. doi: 10.3389/fmed.2018.00088

20. Basu A, Sanchez TW, Casiano CA. DFS70/LEDGFp75: An enigmatic autoantigen at the interface between autoimmunity, AIDS, and cancer. Front Immunol. 2015;6:116. doi: 10.3389/fimmu.2015.00116

21. Pisetsky DS. Antinuclear antibody testing – misunderstood or misbegotten? Nat Rev Rheumatol. 2017;13(8):495-502. doi: 10.1038/nrrheum.2017.74

22. Pascolini S, Vannini A, Deleonardi G, Ciordinik M, Sensoli A, Carletti I, et al. COVID-19 and immunological dysregulation: Can autoantibodies be useful? Clin Transl Sci. 2021;14(2):502-508. doi: 10.1111/cts.12908

23. Gazzaruso C, Carlo Stella N, Mariani G, Nai C, Coppola A, Naldani D, et al. High prevalence of antinuclear antibodies and lupus anticoagulant in patients hospitalized for SARS-CoV2 pneumonia. Clin Rheumatol. 2020;39(7):2095-2097. doi: 10.1007/s10067-020-05180-7

24. Vlachoyiannopoulos PG, Magira E, Alexopoulos H, Jahaj E, Theophilopoulou K, Kotanidou A, et al. Autoantibodies related to systemic autoimmune rheumatic diseases in severely ill patients with COVID-19. Ann Rheum Dis. 2020;79(12):1661-1663. doi: 10.1136/annrheumdis-2020-218009

25. Sacchi MC, Tamiazzo S, Stobbione P, Agatea L, De Gaspari P, Stecca A, et al. SARS-CoV-2 infection as a trigger of autoimmune response. Clin Transl Sci. 2021;14(3):898-907. doi: 10.1111/cts.12953

26. Насонов ЕЛ, Самсонов МЮ, Лила АМ. Коронавирусная болезнь 2019 (COVID-19) и аутоиммунитет. Вестник Российской академии наук. 2022;92(7):654-660. doi: 10.31857/S086958732207012X

27. Mahler M, Fritzler MJ. The clinical significance of the dense fine speckled immunofluorescence pattern on HEp-2 cells for the diagnosis of systemic autoimmune diseases. Clin Dev Immunol. 2012;2012:494356. doi: 10.1155/2012/494356

28. Conrad K, Röber N, Andrade LE, Mahler M. The clinical relevance of anti-DFS70 autoantibodies. Clin Rev Allergy Immunol. 2017;52(2):202-216. doi: 10.1007/s12016-016-8564-5

29. Ochs RL, Stein TW Jr, Peebles CL, Gittes RF, Tan EM. Autoantibodies in interstitial cystitis. J Urol. 1994;151(3):587-592. doi: 10.1016/s0022-5347(17)35023-1

30. Conrad K, Andrade LE, Chan EK, Mahler M, Meroni PL, Pruijn GJ, et al. From autoantibody research to standardized diagnostic assays in the management of human diseases – Report of the 12th Dresden Symposium on Autoantibodies. Lupus. 2016;25(8):787-796. doi: 10.1177/0961203316644337

31. Damoiseaux J, Andrade LEC, Carballo OG, Conrad K, Francescantonio PLC, Fritzler MJ, et al. Clinical relevance of HEp-2 indirect immunofluorescent patterns: The International Consensus on ANA patterns (ICAP) perspective. Ann Rheum Dis. 2019;78(7):879-889. doi: 10.1136/annrheumdis-2018-214436

32. Chan EK, Damoiseaux J, Carballo OG, Conrad K, de Melo Cruvinel W, Francescantonio PL, et al. Report of the First International Consensus on standardized nomenclature of antinuclear antibody HEp-2 cell patterns 2014–2015. Front Immunol. 2015;6:412. doi: 10.3389/fimmu.2015.00412

33. Mahler M, Parker T, Peebles CL, Andrade LE, Swart A, Carbone Y, et al. Anti-DFS70/LEDGF antibodies are more prevalent in healthy individuals compared to patients with systemic autoimmune rheumatic diseases. J Rheumatol. 2012;39(11):2104-2110. doi: 10.3899/jrheum.120598

34. Bizzaro N, Pesente F, Cucchiaro F, Infantino M, Tampoia M, Villalta D, et al. Anti-DFS70 antibodies detected by immunoblot methods: A reliable tool to confirm the dense fine speckles ANA pattern. J Immunol Methods. 2016;436:50-53. doi: 10.1016/j.jim.2016.06.008

35. Malyavantham K, Suresh L. Analysis of DFS70 pattern and impact on ANA screening using a novel HEp-2 ELITE/DFS70 knockout substrate. Autoimmun Highlights. 2017;8(1):3. doi: 10.1007/s13317-017-0091-8

36. Dellavance A, Viana VS, Leon EP, Bonfa ES, Andrade LE, Leser PG. The clinical spectrum of antinuclear antibodies associated with the nuclear dense fine speckled immunofluorescence pattern. J Rheumatol. 2005;32(11):2144-2149.

37. Ochs RL, Muro Y, Si Y, Ge H, Chan EK, Tan EM. Autoantibodies to DFS70kd/transcription coactivator p75 in atopic dermatitis and other conditions. J Allergy Clin Immunol. 2000;105(6 Pt 1):1211-1220. doi: 10.1067/mai.2000.107039

38. Ochs RL, Mahler M, Basu A, Rios-Colon L, Sanchez TW, Andrade LE, et al. The significance of autoantibodies to DFS70/LEDGFp75 in health and disease: integrating basic science with clinical understanding. Clin Exp Med. 2016;16(3):273-293. doi: 10.1007/s10238-015-0367-0

39. Okamoto M, Ogawa Y, Watanabe A, Sugiura K, Shimomura Y, Aoki N, et al. Autoantibodies to DFS70/LEDGF are increased in alopecia areata patients. J Autoimmun. 2004;23(3):257-266. doi: 10.1016/j.jaut.2004.07.004

40. Daniels T, Zhang J, Gutierrez I, Elliot ML, Yamada B, Heeb MJ, et al. Antinuclear autoantibodies in prostate cancer: immunity to LEDGF/p75, a survival protein highly expressed in prostate tumors and cleaved during apoptosis. Prostate. 2005;62(1):14-26. doi: 10.1002/pros.20112

41. Ortiz-Hernandez GL, Sanchez-Hernandez ES, Casiano CA. Twenty years of research on the DFS70/LEDGF autoantibody-autoantigen system: Many lessons learned but still many questions. Auto Immun Highlights. 2020;11(1):3. doi: 10.1186/s13317-020-0126-4

42. Александрова ЕН, Верижникова ЖГ, Новиков АА, Панафидина ТА, Попкова ТВ. Антитела к DFS70 – новый биомаркер для исключения диагноза системной красной волчанки у АНФ-позитивных здоровых лиц. Научно-практическая ревматология. 2017;55(2 Прил 1):8.

43. Александрова ЕН, Новиков АА, Клюквина НГ, Васильев ВИ, Лукина ГВ. Диагностическое значение моноспецифических антител к DFS70 при системных аутоиммунных ревматических заболеваниях. Медицинский алфавит. 2021(33):38-41. doi: 10.33667/2078-5631-2021-33-38-41

44. Ganapathy V, Casiano CA. Autoimmunity to the nuclear autoantigen DFS70 (LEDGF): What exactly are the autoantibodies trying to tell us? Arthritis Rheum. 2004;50(3):684-688. doi: 10.1002/art.20095

45. Miyara M, Albesa R, Charuel JL, El Amri M, Fritzler MJ, Ghillani-Dalbin P, et al. Clinical phenotypes of patients with antiDFS70/LEDGF antibodies in a routine ANA referral cohort. Clin Dev Immunol. 2013;2013:703759. doi: 10.1155/2013/703759

46. Mariz HA, Sato EI, Barbosa SH, Rodrigues SH, Dellavance A, Andrade LE. Pattern on the antinuclear antibody-HEp-2 test is a critical parameter for discriminating antinuclear antibody-positive healthy individuals and patients with autoimmune rheumatic diseases. Arthritis Rheum. 2011;63(1):191-200. doi: 10.1002/art.30084

47. Watanabe A, Kodera M, Sugiura K, Usuda T, Tan EM, Takasaki Y, et al. Anti-DFS70 antibodies in 597 healthy hospital workers. Arthritis Rheum. 2004;50(3):892-900. doi: 10.1002/art.20096

48. Schmeling H, Mahler M, Levy DM, Moore K, Stevens AM, Wick J, et al. Autoantibodies to dense fine speckles in pediatric diseases and controls. J Rheumatol. 2015;42(12):2419-2426. doi: 10.3899/jrheum.150567

49. Peker BO, Şener AG, Tarhan EF, Kaya S. Investigation of antiDFS70 antibody in patients with systemic autoimmune rheumatic diseases. Clin Rheumatol. 2019;(38):3627-3633. doi: 10.1007/s10067-019-04730-y

50. Choi MY, Clarke AE, St Pierre Y, Hanly JG, Urowitz MB, Romero-Diaz J, et al. The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients. Lupus. 2017;26(10):1051-1059. doi: 10.1177/0961203317692437

51. Muro Y, Sugiura K, Nakashima R, Mimori T, Akiyama M. Low prevalence of anti-DFS70/LEDGF antibodies in patients with dermatomyositis and other systemic autoimmune rheumatic diseases. J Rheumatol. 2013;40(1):92-93. doi: 10.3899/jrheum.121168

52. Infantino M, Carbone T, Manfredi M, Grossi V, Benucci M, Blank M, et al. Are anti-DFS70 autoantibodies protective? Isr Med Assoc J. 2019;21(8):509-511.

53. Infantino M, Shovman O, Pérez D, Manfredi M, Grossi V, Benucci M, et al. Anti-DFS70 autoantibodies in undifferentiated connective tissue diseases subjects: What’s on the horizon? Rheumatology (Oxford). 2018;57(7):1293-1298. doi: 10.1093/rheumatology/key012

54. Aljadeff G, Shemer A, Katz I, Andrade LEC, Gilburd B, Halpert G, et al. Infusion of anti-DFS70 antibodies prolonged survival of lupus-prone mice. Lupus. 2021;30(2):320-324. doi: 10.1177/0961203320969976